May 1, 2014

Esperion Therapeutics to Deliver Three Scientific Poster Presentations at the 2014 Annual Scientific Sessions of the National Lipid Association

ANN ARBOR, Mich.--(BUSINESS WIRE)-- Esperion Therapeutics, Inc. (Nasdaq: ESPR) today announced the company will deliver three posters featuring ETC-1002 Phase 2 clinical results at the 2014 Annual Scientific Sessions of the National Lipid Association in Orlando, Fla. The posters provide additional information from previously-presented Phase 2 studies of ETC-1002, and new analyses regarding blood pressure lowering in patients with both hypercholesterolemia and mildly elevated blood pressure.

The first, poster 155, *"ETC-1002 Lowers LDL-Cholesterol and is Well Tolerated in Hypercholesterolemic Patients across Four Phase 2a Studies,"* concludes ETC-1002 significantly lowered low-density lipoprotein cholesterol (LDL-C), reduced high sensitivity C-reactive protein (hsCRP), and was well-tolerated in the four studies.

The second, poster 156, *"ETC-1002 Lowers LDL-Cholesterol and is Well Tolerated in Hypercholesterolemic Patients with Statin Intolerance,"* concludes ETC-1002 demonstrated a 32 percent lowering of LDL-C, and a reduction of 42 percent in hsCRP levels in patients who had failed two or more statins due to muscle-related side effects. ETC-1002 was also well-tolerated, and muscle-related adverse events were similar in the ETC-1002 and placebo groups.

The third and final, poster 172, "*ETC-1002 Reduces Blood Pressure in Hypercholesterolemic Patients with Mildly Elevated Blood Pressure,"* showed that ETC-1002 significantly reduced systolic blood pressure by 6.68 mmHg compared to placebo in a pooled post hoc sub-group analysis of four phase 2a studies in hypercholesterolemic patients with mildly elevated blood pressure.

"As we continue to advance ETC-1002 for LDL-C lowering in hypercholesterolemic patients who are intolerant to statins," said Tim M. Mayleben, president and chief executive officer of Esperion Therapeutics, "we have observed that ETC-1002 may also have the potential to lower elevated blood pressure, another important cardiometabolic risk marker. We plan to explore this in future clinical studies to more fully understand the benefits of ETC-1002."

All three posters will be presented during two scheduled sessions; Friday, May 2 at 11:35 a.m., and Saturday, May 3 at 12:00 p.m. The full posters are available for online viewing at www.investor.esperion.com/events, and abstracts presented at the meeting will be published in the *Journal of Clinical Lipidology.*

About Esperion Therapeutics

Esperion Therapeutics, Inc. is a clinical stage biopharmaceutical company focused on developing and commercializing first-in-class, oral, low-density lipoprotein cholesterol (LDL-C) lowering therapies for the treatment of patients with hypercholesterolemia and other cardiometabolic risk markers. ETC-1002, Esperion's lead product candidate, is a unique, first-in-class, orally available, once-daily small molecule designed to lower LDL-cholesterol levels and avoid the side effects associated with the currently-available LDL-cholesterol lowering therapies. ETC-1002 is being developed primarily for patients intolerant of statins with elevated levels of LDL-cholesterol. Phase 2b clinical trials for ETC-1002 are currently underway and build upon a successful and comprehensive Phase 1 and Phase 2 program. For more information, please visit www.esperion.com.

Forward Looking Statements

This press release contains forward-looking statements that are made pursuant to the safe harbor provisions of the federal securities laws, including statements regarding the therapeutic potential of ETC-1002 and the anticipated timing for reporting top-line results from Esperion's Phase 2b ETC-1002-008 clinical study and Esperion's Phase 2b ETC-1002-009 clinical study. Any statements contained in this press release that are not statements of historical fact may be deemed to be forward-looking statements. Forward-looking statements involve risks and uncertainties that could cause Esperion's actual results to differ significantly from those projected, including, without limitation, the risk that unanticipated developments could interfere with the development (and commercialization) of ETC-1002, as well as other risks detailed in Esperion's filings with the Securities and Exchange Commission, including our Annual Report on Form 10-K filed with Securities and Exchange Commission on March 13, 2014. You are cautioned not to place undue reliance on the forward-looking statements, which speak only as of the date of this release. Esperion disclaims any obligation or undertaking to update or revise any forward-looking statements contained in

this press release, other than to the extent required by law.

Media Contact:
W2O Group
Elliot Fox, 212.257.6724
efox@w2ogroup.com

Source: Esperion Therapeutics, Inc.